FDA advisers back GW’s Epidiolex for rare epilepsy
UK firm’s potential blockbuster on course for approval
X
FDA advisers back GW’s Epidiolex for rare epilepsy
https://pharmaphorum.com/news/fda-advisers-back-gws-epidiolex-for-rare-epilepsy/
UK & Europe
UK & Europe
GSK sells rare disease drugs, including groundbreaking Strimvelis
CEO Walmsley opts to focus on blockbuster medicines
Owlstone adds AstraZeneca to roster of Breath Biopsy partners
Owlstone Medical, one of the UK’s most promising medtech start-ups, is continuing its expansion into pharma partnering via a new deal with AstraZeneca.
‘Sugar tax’ already working, say health campaigners
Many drinks manufacturers have changed recipes to avoid tax
Biogen gets go-ahead for EU Humira launch in October
But deal with Samsung prevents US launch until mid-2023
NI digital “hub” aims to improve youngsters’ mental health
Hub offers help and advice for young people aged up to 25
Cut use of antibiotics in nursing homes, pharmacists say
Pharmacists could train staff to cut prescriptions